Diagnostic value of urinary luteinizing hormone levels in the monitoring of precocious puberty treatment

Basit Öğe Kaydı
dc.authoridCELIK, Nurullah/0000-0003-1583-6807
dc.authoridBideci, Aysun/0000-0003-0302-414X
dc.contributor.authorYuce, Ozge
dc.contributor.authorBideci, Aysun
dc.contributor.authorCelik, Nurullah
dc.contributor.authorCamurdan, Orhun
dc.contributor.authorCinaz, Peyami
dc.date.accessioned2024-10-26T18:09:54Z
dc.date.available2024-10-26T18:09:54Z
dc.date.issued2020
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractObjective: To determine whether first-voided urinary LH (FV-ULH) - level measurement can adequately assess pubertal suppression as much as standard tests can. Subjects and methods: The study group included patients with central precocious puberty and rapidly progressing early puberty who received up to 3 - 4 doses of GnRHa therapy monthly and did not have adequate hormonal suppression after GnRH stimulation (90-minute LH level > 4 IU/L). Design: All of the participants underwent an LHRH test just after admission to the study. According to the stimulated peak LH levels, the patients were divided into 2 groups and followed until the end of the first year of treatment.The concordance between FV-ULH and stimulated LH levels was assessed. Results: The FV-ULH levels in patients with inadequate hormonal suppression were significantly high compared to patients with adequate hormonal suppression. FV-ULH levels were very strongly correlated with stimulated LH levels (r = 0.91). Its correlation with basal LH levels was significant (r = 0.65). However, this positive correlation was modestly weakened after the first year of treatment.The cutoff value for FV-ULH of 1.01 mlU/mL had the highest sensitivity (92.3%) and specificity (100%). Conclusion: FV-ULH levels, using more reliable and sensitive assay methods, can be used to monitor the adequacy of GnRHa therapy.
dc.identifier.doi10.20945/2359-3997000000212
dc.identifier.endpage127
dc.identifier.issn2359-3997
dc.identifier.issn2359-4292
dc.identifier.issue2
dc.identifier.pmid32236310
dc.identifier.scopus2-s2.0-85084263716
dc.identifier.scopusqualityQ3
dc.identifier.startpage121
dc.identifier.urihttps://doi.org/10.20945/2359-3997000000212
dc.identifier.urihttps://hdl.handle.net/20.500.12418/30334
dc.identifier.volume64
dc.identifier.wosWOS:000532471900005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSbem-Soc Brasil Endocrinologia & Metabologia
dc.relation.ispartofArchives of Endocrinology Metabolism
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectMonitoring
dc.subjectprecocious puberty
dc.subjecturinary gonadotropin
dc.subjectGnRH analogues
dc.titleDiagnostic value of urinary luteinizing hormone levels in the monitoring of precocious puberty treatment
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu